Stay updated with breaking news from Pascal Deschatelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 16,770,000 shares, an increase of 23.2% from the September 15th total of 13,610,000 shares. Based on an average daily volume of 5,100,000 shares, […]
On October 9, 2023, Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals Inc (NASDAQ:APLS), sold 12,000 shares of the company.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $37.62, but opened at $36.54. Apellis Pharmaceuticals shares last traded at $37.41, with a volume of 1,363,581 shares traded. Wall Street Analysts Forecast Growth Several analysts have recently issued reports on […]
EcoR1 Capital LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 5.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,451,647 shares of the company’s stock after purchasing an additional 268,216 shares during the quarter. Apellis […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) insider Pascal Deschatelets sold 12,000 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $42.87, for a total value of $514,440.00. Following the transaction, the insider now owns 1,059,813 shares in the company, valued […]